



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Liu et al.

SERIAL NO.:

10/643,752

**GROUP NO.:** 

1637

FILING DATE:

August 19, 2003

**EXAMINER:** 

Jezia Riley

TITLE:

**Evolving New Molecular Function** 

## CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of June, 2005.

Carrah Malone

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

### Submitted herewith is/are:

- 1. Transmittal Form (1 page);
- 2. Supplemental Information Disclosure Statement (3 pages);
- 3. Form PTO 1449 (1 page);
- 4. Copy of cited reference C218; and
- 5. Return Receipt Postcard.

VER 9/00

	CIES :								
7	٠ ''دَرِ		Application	Serial Number		10/643,752			
	JUN 1 0 2005 E	Filing Date		1	August 19, 2003				
\ \#	S. C.	First Named Inventor			Liu				
×	TRANSMITTA	Group Art Unit			1637				
		Examiner Name			Jezia Riley				
	FORM		Attorney Do	ocket No.		LS5-001 Not applicable			
			Patent No.						
			Issue Date			Not applicable			
		ENG	CLOSURES (c	heck all that apply)					
П	Fee Transmittal Form			e to File Missing	Γ	Notice of Appeal to Board			
			Parts of Applie		T=	of Patent Appeals and			
	☐ Check Attached				111	nerrerences			
	Copy of Fee Transmittal Form		Formal Drawin	ng(s)		Appeal Brief (in triplicate)			
	Amendment/Response		Request For Co	ontinued	╏┎	Status Inquiry			
	☐ Preliminary	Examination (RC Transmittal		RCE)		·			
	After Final				Þ	Return Receipt Postcard			
	☐ Affidavits/declaration(s)☐ Letter to Official		Power of Attor	rney Prior Powers)	Þ	Certificate of First Class Mailing			
	Draftsperson		(Iterocanon of		-	under 37 C.F.R. 1.8			
	including Drawings [Total Sheets]		Terminal Disc	laimer					
						Transmission under 37 C.F.R. 1.8			
	Petition for Extension of			aration and Power					
	Time		of Attorney for Utility or Design Patent Application			(please identify below)			
$\boxtimes$	Supplemental Information		Small Entity Statement						
	Disclosure Statement	_	S 2, S						
	Form PTO-1449 Copy of Supp. IDS		CD(s) for large	e table or computer					
	Citation C218		program						
	Certified Copy of Priority		Amendment A	fter Allowance					
	Document(s)		Request for Ce	ertificate of					
	Sequence Listing submission		Correction	of Correction (in					
	☐ Paper Copy/CD☐ Computer Readable Copy		duplicate)	of Correction (in					
	Statement verifying								
identity of above  CORRESPONDENCE ADDRESS				SIGNATURE BL	$\frac{1}{0}$	, K			
				SIGNATURE BE	<u>UC</u>	Respectfully submitted,			
Direct all correspondence to: Patent Administrator Goodwin Procter LLP Exchange Place Boston, MA 02109			,			0112-11			
				Date: June 8, 2005		WW. Journell			
	Tel. No.:	1000	Reg. No. 38,678 Tel. No.: (617) 570-	_12	Duncan A. Greenhalgh  Attorney for Applicant				
	Fax No.: ( Customer		Fax No.: (617) 523-12		31 Goodwin Procter LLP				
	Customer	1 <b>-1</b>			Exchange Place Boston, MA 02109				
L						DUSIUM, IVIA UZIUZ			

VER 12/00



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Liu et al.

CONF. NO.:

4082

**SERIAL NO.:** 

10/643,752

**GROUP NO.:** 

1637

FILING DATE:

August 19, 2003

**EXAMINER:** 

Jezia Riley

TITLE:

**Evolving New Molecular Function** 

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

In addition, Applicants wish to inform the Examiner about the following U.S. patent applications and the contents of their file wrappers, including all Office actions issued therein:

- 1. U.S.S.N. 11/141,542, entitled "Evolving New Molecular Function," filed on May 31, 2005; and
- 2. U.S.S.N. 11/141,164, entitled "Evolving New Molecular Function," filed on May 31, 2005.

Information about other patent applications can be found in Applicant's Information Disclosure Statement filed on May 6, 2005.

Serial No. 10/643,752

Page 2 of 3

### REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):  $\boxtimes$ within three (3) months of the filing date of a national application other than a (1) continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or after the period defined in (1) but before the mailing date of a final action or a notice (2) of allowance under 37 C.F.R. 1.311, and the requisite Statement is below, OR the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or (3) after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND the requisite Statement is below, AND  $\Box$ the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein. It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application. **STATEMENT** As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]: Each item of information contained in the Information Disclosure Statement was 1. first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign

application, and, to the knowledge of the person signing this Statement after

Supplemental Information Disclosure Statement Serial No. 10/643,752 Page 3 of 3

making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: June 8, 2005 Reg. No. 38,678

Tel. No.: (617) 570-1299 Fax No.: (617) 523-1231

VER 11/03 2466309 Respectfully submitted,

Duncan A. Greenhalgh Attorney for Applicants Goodwin Procter LLP Exchange Place

Boston, Massachusetts 02109

Customer No. 051414



FORM PTO - 1449 SUPPLEMENTAL INFORMATION					A	ATTORNEY DOCKET NO.: LS5-001							
					А	APPLICANT(S): Liu et al.							
DISCLOSURE STATEMENT						SERIAL NO.: 10/643,752							
			F	FILING DATE: August 19, 2003 GROUP: 1637									
			U.S. 1	PATE	NT D	OCUME	NTS						
EXAM. INIT.		DOCUMENT DATE NUMBER		N/	NAME			CLASS	SUB CLASS	1	FILING DATE IF APPROPRIATE		
	A71	2003/0099945	099945 05/29/2003			3 Eaton et al.				07/30/2001			
	A72	6,048,698	04/11/200	0 Ea	Eaton et al.					09/21	09/21/1998		
	1.71			9 Ea	Eaton et al.					03/20/1996			
				aton <i>et</i>	al.			09/20/1994					
			FOREIG	N PA	TEN	r Docui	MENTS	3					
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE		CLASS	SUB CLASS	FILING DATE	G ABSTRACT ONLY		ENGLISH LANG (Y/N)		
		(	OTHER AR	Γ, JOI	JRNA	L ARTIO	CLES, I	ETC.					
EXAM. INIT.	ОТН	ER DOCUMENTS	DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)										
	C218 Dewey et al., "Integrated drug discovery technology in a test tube," www.currentdrugdiscovery.com (July 2002)												

DATE CONSIDERED

VER 9/00

**EXAMINER**